Compare Davita Inc (DVA) vs iShares MSCI Taiwan ETF (EWT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs iShares MSCI Taiwan ETF — how do they compare? Davita Inc trades at $226.2 (market cap $14.92B), while iShares MSCI Taiwan ETF trades at $102.65. Which is the better fit depends on your goals.
| DVA | EWT | |
|---|---|---|
Market Cap | $14.92B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $235.71 | $111.53 |
52-Week Low | $103.87 | $58.05 |
Enterprise Value | $27.47B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
EWT, the iShares MSCI Taiwan ETF, trades at $101.88, down 4.04% on the day amid a bearish technical signal. The ETF has delivered strong returns in 2026, more than doubling from its 2025 close, driven by Taiwan's critical role in the global semiconductor and AI supply chain. However, key financial ratios are unavailable, and the technical outlook is mixed, with moving averages bullish but oscillators neutral.
The outlook for EWT is clouded by geopolitical tensions with China and potential currency volatility, though its exposure to the AI-driven semiconductor boom offers significant growth potential. Investors face a trade-off between high-reward tech exposure and substantial geopolitical risk, with the current price near key support levels suggesting a cautious near-term stance is warranted.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →
